Market LIVE
Published markets; coverage varies by country
Product profile · United States

LINZESS

 ·  Patent Litigation & Settlement History ↓

IngredientLINACLOTIDE
Application typeNDA
Application202811
Product001
Dosage formCAPSULE
RouteORAL
Strength145MCG
Approval date2012-08-30
Marketing statusPrescription
Status event—
ApplicantABBVIE
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2021-02-09
Status event—

Final ANDA candidate 209564/001 on 2021-02-09. Source-level RLD/TE screen; earliest Final and exact Product source reference require independent review.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
73040362026-08-30DS/DP/U U-1516———
———
73040362026-08-30DS/DP/U U-1278———
———
73040362026-08-30DS/DP/U U-4345———
———
73040362027-02-28— ————
—2027-02-28—
89330302031-02-17DP/U U-4345———
———
89330302031-08-17— ————
—2031-08-17—
87485732031-10-30U U-4345———
———
87485732031-10-30U U-1515———
———
87485732031-10-30U U-1516———
———
88026282031-10-30DP ————
———
87485732032-04-30— ————
—2032-04-30—
88026282032-04-30— ————
—2032-04-30—
97083712033-08-16DP/U U-1515———
———
97083712033-08-16DP/U U-1516———
———
97083712033-08-16DP/U U-4345———
———
97083712034-02-16— ————
—2034-02-16—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
I-921—2026-06-12————Source
NPP—2028-11-04————Source
PED—2029-05-04————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
209564 / 001FINAL_APPROVAL · FINAL_APPROVED2021-02-09—MYLAN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209611 / 001FINAL_APPROVAL · FINAL_APPROVED2023-02-07—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 2 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
209564 / 001MYLAN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-02-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209611 / 001AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2023-02-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.